Celularity (CELU)
(Real Time Quote from BATS)
$2.92 USD
0.00 (0.00%)
Updated Sep 25, 2024 10:38 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CELU 2.92 0.00(0.00%)
Will CELU be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CELU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELU
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
CELU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Other News for CELU
Celularity to Present at H.C. Wainwright?s 26th Annual Global Investment Conference
Celularity Appoints Richard J. Berman to its Board of Directors
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Celularity receives noncompliance notification from Nasdaq
Celularity receives Nasdaq notice regarding late Form 10-Q filing